Literature DB >> 27456363

Reprogramming bladder cancer cells for studying cancer initiation and progression.

Banu Iskender1,2, Kenan Izgi3,4, Halit Canatan5,3.   

Abstract

The induced pluripotent stem cell (iPSC) technology is the forced expression of specific transcription factors in somatic cells resulting in transformation into self-renewing, pluripotent cells which possess the ability to differentiate into any type of cells in the human body. While malignant cells could also be reprogrammed into iPSC-like cells with lower efficiency due to the genetic and epigenetic barriers in cancer cells, only a limited number of cancer cell types could be successfully reprogrammed until today. In the present study, we aimed at reprogramming two bladder cancer cell lines HTB-9 and T24 using a non-integrating Sendai virus (SeV) system. We have generated six sub-clones using distinct combinations of four factors-OCT4, SOX2, KLF4 and c-MYC-in two bladder cancer cell lines. Only a single sub-clone, T24 transduced with 4Fs, gave rise to iPSC-like cells. Bladder cancer cell-derived T24 4F cells represent unique features of pluripotent cells such as epithelial-like morphology, colony-forming ability, expression of pluripotency-associated markers and bearing the ability to differentiate in vitro. This is the first study focusing on the reprogramming susceptibility of two different bladder cancer cell lines to nuclear reprogramming. Further molecular characterisation of T24 4F cells could provide a better insight for biomarker research in bladder carcinogenesis and could offer a valuable tool for the development of novel therapeutic approaches in bladder carcinoma.

Entities:  

Keywords:  Bladder cancer; HTB-9; Induced pluripotent stem cells; Pluripotency; Reprogramming; T24

Mesh:

Substances:

Year:  2016        PMID: 27456363     DOI: 10.1007/s13277-016-5226-4

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  16 in total

Review 1.  Induced pluripotent stem cells: opportunities and challenges.

Authors:  Keisuke Okita; Shinya Yamanaka
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-08-12       Impact factor: 6.237

2.  Generation of induced pluripotent stem cells from human cord blood cells with only two factors: Oct4 and Sox2.

Authors:  Alessandra Giorgetti; Nuria Montserrat; Ignacio Rodriguez-Piza; Carmen Azqueta; Anna Veiga; Juan Carlos Izpisúa Belmonte
Journal:  Nat Protoc       Date:  2010-04-01       Impact factor: 13.491

3.  Aberrant epigenetic silencing of tumor suppressor genes is reversed by direct reprogramming.

Authors:  Shulamit Ron-Bigger; Ori Bar-Nur; Sara Isaac; Michael Bocker; Frank Lyko; Amir Eden
Journal:  Stem Cells       Date:  2010-08       Impact factor: 6.277

Review 4.  Pluripotent stem cell-based disease modeling: current hurdles and future promise.

Authors:  Nadja Zeltner; Lorenz Studer
Journal:  Curr Opin Cell Biol       Date:  2015-11-27       Impact factor: 8.382

5.  Reprogramming using microRNA-302 improves drug sensitivity in hepatocellular carcinoma cells.

Authors:  Chikato Koga; Shogo Kobayashi; Hiroaki Nagano; Yoshito Tomimaru; Naoki Hama; Hiroshi Wada; Koichi Kawamoto; Hidetoshi Eguchi; Masamitsu Konno; Hideshi Ishii; Koji Umeshita; Yuichiro Doki; Masaki Mori
Journal:  Ann Surg Oncol       Date:  2014-04-18       Impact factor: 5.344

6.  Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors.

Authors:  Jeong Beom Kim; Holm Zaehres; Guangming Wu; Luca Gentile; Kinarm Ko; Vittorio Sebastiano; Marcos J Araúzo-Bravo; David Ruau; Dong Wook Han; Martin Zenke; Hans R Schöler
Journal:  Nature       Date:  2008-06-29       Impact factor: 49.962

7.  Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming.

Authors:  X Zhang; F D Cruz; M Terry; F Remotti; I Matushansky
Journal:  Oncogene       Date:  2012-07-09       Impact factor: 9.867

8.  Comparative proteomic analysis of supportive and unsupportive extracellular matrix substrates for human embryonic stem cell maintenance.

Authors:  Despina Soteriou; Banu Iskender; Adam Byron; Jonathan D Humphries; Simon Borg-Bartolo; Marie-Claire Haddock; Melissa A Baxter; David Knight; Martin J Humphries; Susan J Kimber
Journal:  J Biol Chem       Date:  2013-05-08       Impact factor: 5.157

Review 9.  Role of tumor suppressor genes in the cancer-associated reprogramming of human induced pluripotent stem cells.

Authors:  Ying-Chu Lin; Yoshinobu Murayama; Koichiro Hashimoto; Yukio Nakamura; Chang-Shin Lin; Kazunari K Yokoyama; Shigeo Saito
Journal:  Stem Cell Res Ther       Date:  2014       Impact factor: 6.832

Review 10.  Human induced pluripotent stem cells from basic research to potential clinical applications in cancer.

Authors:  Teresa de Souza Fernandez; Cecilia de Souza Fernandez; André Luiz Mencalha
Journal:  Biomed Res Int       Date:  2013-10-28       Impact factor: 3.411

View more
  9 in total

Review 1.  Current status in cancer cell reprogramming and its clinical implications.

Authors:  Kenan Izgi; Halit Canatan; Banu Iskender
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-12       Impact factor: 4.553

Review 2.  Application of induced pluripotency in cancer studies.

Authors:  Patrycja Czerwińska; Sylwia Mazurek; Maciej Wiznerowicz
Journal:  Rep Pract Oncol Radiother       Date:  2018-04-24

Review 3.  Modeling the process of human tumorigenesis.

Authors:  Sneha Balani; Long V Nguyen; Connie J Eaves
Journal:  Nat Commun       Date:  2017-05-25       Impact factor: 14.919

Review 4.  Cancer cell reprogramming: a promising therapy converting malignancy to benignity.

Authors:  Lanqi Gong; Qian Yan; Yu Zhang; Xiaona Fang; Beilei Liu; Xinyuan Guan
Journal:  Cancer Commun (Lond)       Date:  2019-08-29

5.  Reprogramming of Cancer Cells into Induced Pluripotent Stem Cells Questioned.

Authors:  Jin Seok Bang; Na Young Choi; Minseong Lee; Kisung Ko; Yo Seph Park; Kinarm Ko
Journal:  Int J Stem Cells       Date:  2019-11-30       Impact factor: 2.500

Review 6.  Cellular Reprogramming-A Model for Melanoma Cellular Plasticity.

Authors:  Karol Granados; Juliane Poelchen; Daniel Novak; Jochen Utikal
Journal:  Int J Mol Sci       Date:  2020-11-05       Impact factor: 5.923

Review 7.  Cancer cells as a new source of induced pluripotent stem cells.

Authors:  Azam Shamsian; Roxana Sahebnasagh; Amir Norouzy; Safin Hassan Hussein; Mohammad Hossein Ghahremani; Zahra Azizi
Journal:  Stem Cell Res Ther       Date:  2022-09-05       Impact factor: 8.079

8.  "Reprogram Enablement" as an Assay for Identifying Early Oncogenic Pathways by Their Ability to Allow Neoplastic Cells to Reacquire an Epiblast State.

Authors:  Yanjun Kong; Ryan C Gimple; Rachael N McVicar; Andrew P Hodges; Jun Yin; Yang Liu; Weiwei Zhan; Evan Y Snyder
Journal:  Stem Cell Reports       Date:  2020-08-13       Impact factor: 7.765

Review 9.  Cell Fate Reprogramming in the Era of Cancer Immunotherapy.

Authors:  Olga Zimmermannova; Inês Caiado; Alexandra G Ferreira; Carlos-Filipe Pereira
Journal:  Front Immunol       Date:  2021-07-21       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.